Major lipids, apolipopro- teins, and risk of vascular disease. JAMA. 2009;302:1993 2000. S2.2-6. Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus non- fasting low-density lipoprotein cholesterol levels on long-term mor- tality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014;130:546 53. S2.2-7. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62:732 9. S2.2-8. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061 8. S2.2-9. Sathiyakumar V, Park J, Golozar A, et al. Fasting versus nonfast- ing and low-density lipoprotein cholesterol accuracy. Circulation. 2018;137:10 9. S2.2-10. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not rou- tinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentra- tion cut-points a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37:1944 58. S2.2-11. Mora S, Rifai N, Buring JE, et al. Fasting compared with nonfast- ing lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118:993 1001. S2.2-12. Brunzell JD, Albers JJ, Chait A, et al. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceride- mia. J Lipid Res. 1983;24:147 55. S2.2-13. Sniderman AD, Tremblay A, De Graaf J, et al. Phenotypes of hyper- triglyceridemia caused by excess very-low-density lipoprotein. J Clin Lipidol. 2012;6:427 33. 2.3. Measurements of Apolipoprotein B and Lipoprotein (a) S2.3-1. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low- density lipoprotein cholesterol, non-high-density lipoprotein choles- terol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337 45. S2.3-2. 